Anti-CSPG4 fusions with interferon for the treatment of malignancy

US10822427B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Sherie L. Morrison · Los Angeles, US
• John M. Timmerman · Los Angeles, US
• Kham M. Trinh · Alhambra, US

Key dates

• Filing date: Oct 2, 2018
• Grant date: Nov 3, 2020
• Expiry date: Oct 2, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-α) or to a mutant interferon alpha or to an interferon beta (IFN-β) or to a nutant interferon beta, or to an interferon gamma (IFN-γ) or to a mutant interferon gamma.